2025-06-11-Jefferies-提醒_关于带量采购_关税和体外诊断市场趋势的专家电话会议-明天美国东部时间上午9点_9页_131kb

报告摘要

Equity Research Summary: Life Science Tools & Diagnostics

Event Reminder

An expert call will be held on Friday, June 13, 2025, at 9:00 AM ET. The speaker is Wenxin (Vincent) Ma, General Manager of Sales and Marketing at Shandong Accurdx Biotechnology. Interested parties should register via the link provided.

Call Details

Speaker: Wenxin (Vincent) Ma

Over 30 years of experience in China's IVD market.
Previously held director-level sales roles at Sysmex, Biomerieux, Beckman Coulter Diagnostics (Danaher), and Thermo Fisher.
GM of Sales and Marketing at Shandong Accurdx Biotechnology, a provider of specialty IVD instruments and reagents.

Discussion Topics

Evolving federal reimbursement and VBP policies.
Trade policy shifts, tariffs, and IVD exemptions.
Pricing, local competitive landscape, and market share dynamics.
Emerging trends and structural shifts in China's IVD market.

Analyst Call on Federal Policies, Tariffs, and IVD Markets

Relevant stock tickers mentioned: BIO, DHR, QGEN, QDEL, RVTY, TMO.

Company Valuations and Risks

Bio-Rad Laboratories (BIO)

Price Target: $270
Rating: Hold
Key Risks: Execution, margin expansion, CEO succession, M&A, ASP pressures in Diagnostics.

Danaher Corp. (DHR)

Price Target: $230
Rating: Buy
Key Risks: Bioprocess demand recovery, reimbursement pressure, lower COVID testing demand.

Qiagen (QGEN)

Price Target: $54
Rating: Buy
Key Risks: QuantiFERON market share loss, weakness in A&G and biopharma, NPI delays, slower dPCR growth.

Revvity Inc. (RVTY)

Price Target: $106
Rating: Hold
Key Risks: Macro economic conditions, new product adoption, margin expansion.

Thermo Fisher Scientific Inc. (TMO)

Price Target: $560
Rating: Buy
Key Risks: M&A missteps, biopharma slowdown, slower China recovery.

Analyst Certification and Jefferies Ratings

Franchise Picks: Includes stock selections from Jefferies equity analysts, only "Buy" rated stocks.
Risks: Equity Research reports are based on specific methodologies, including DCF analysis, EV/EBITDA, P/E, P/CF, and other factors. Reports contain forward-looking statements and investments are subject to market and other risks.